Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- IBL Pairs Up with South Korea’s SML for SFTS Therapy Development
June 21, 2024
- SanBio Says Its Lead Cell Therapy Could Be Shipped from 2025 If All Goes Well
June 21, 2024
- Astellas CEO’s Pay Tops 400 Million Yen in FY2023: Securities Report
June 21, 2024
- Gilead Eager to See More Authorized CAR-T Treatment Centers in Japan
June 21, 2024
- Tsumura Looks to Plant “Guidepost” for Development of Botanical Drugs in US
June 20, 2024
- Healios, Astellas Team Up for RPE Cell Production Method
June 20, 2024
- Zeria Doles Out Acofide Rights to Agastra in Europe, North America
June 20, 2024
- Concerns Grow over Supply of Cephem Antibiotics after Choseido Plant Halt
June 19, 2024
- J-TEC Files JACC for Label Expansion into Knee Osteoarthritis
June 19, 2024
- Otsuka, Ionis Extend HAE Licensing Pact into Asia
June 19, 2024
- Kidswell Bio, Chiome Hook Up on Biosimilar Development
June 19, 2024
- Mitsubishi Offloads Argatroban Business in Europe to Ethypharm
June 19, 2024
- Daiichi Sankyo President Reels in 200 Million Yen-Plus Pay in FY2023
June 19, 2024
- Takeda Bags Option to Ascentage’s CML Drug
June 18, 2024
- Takeda’s Epilepsy Drug Misses Mark in Two PIII Studies
June 18, 2024
- Kunio Takeda, Former CEO of Takeda Pharmaceutical, Dies at 84
June 18, 2024
- India’s Biocon to Set Up Japan Office to Make Full Inroads into Generic API Sector
June 18, 2024
- MSD Files Prevymis for Pediatric Use, Granules Form in Japan
June 17, 2024
- Eisai CEO’s Son Promoted to Representative Officer & EVP
June 17, 2024
- Eisai CEO’s Pay Tops 200 Million Yen: Securities Report
June 17, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…